Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed us to keep our supply chain intact ensuring that our manufacturing operations continued with zero downtime and enabled us to uphold our commitments to our customers.

Proactive risk identification
Anticipating the supply chain risk well before COVID-19 was declared a global pandemic, we conducted a survey covering all our partners, especially in the affected countries, to assess the risk and get a granular understanding of the extent of supply impact across various projects. This timely and detailed information helped our supply chain team develop various strategies to mitigate or minimize the impact.

Translating plans to actions
For an intense period of close to ten weeks, all our cross-functional teams and external partners sustained a 24 x 7 operating model spanning various time zones and implementing solutions in real-time. The team shifted all pending orders in highly affected zones to partners located in medium and low impact zones, by leveraging the strong relationships built over time. We also increased the share of supplies from partners located in less impacted regions. Once the materials were ready, their movement posed a considerable challenge. The team had to reroute several shipments adopting complex logistics solutions involving multi-mode, multi-continent and multi 3PL operators. We used all functional entry gateways, both airports and seaports, which were functional for both inbound and outbound shipments.

Gratifying outcome of collaborative effort
The team handled a total of 294 shipments from the start of lockdown, honouring the delivery commitment to the customers with OTIF > 97% while ensuring zero downtime in the manufacturing activity. Most importantly, the entire effort demonstrated the strength and resilience of our relationships, and an unwavering zeal to make it better together.

Share article

More News

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more

2026.03.25

Kudikunta Lake restoration completed, marking the revival of an urban water body

Kudikunta Lake in Kondapur, Hyderabad, was inaugurated on February 28th following the completion of restoration efforts undertaken by Sai Life Sciences as part of its Corporate Social Responsibility (CSR) initiative in collaboration with the Society for Advancement of Human Endeavour (SAHE). The event marked the culmination of several months of work to restore a previously […]
Read more

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more